Main Article Content
The aim of the present work is to Develop and Characterize controlled release of Zidovudine matrix tablets used for treatment of HIV infection. Development of CR Zidovudine is proposed considering the adverse event profile and high fluctuation index of Zidovudine observed with IR dosage forms. In the present work, attempts were made to formulate and evaluate controlled release of matrix tablets of Zidovudine. Zidovudine was subjected to Preformulation studies; based on the results obtained Zidovudine controlled release tablets were successfully formulated. Formulations prepared by wet granulation using HPMC and carbopol 934 as control release polymers and 5% W/W of povidone in isopropyl alcohol as binder solution have showed desired in vitro release. Set of trials were formulated for which Zidovudine evaluated parameters (bulk density, tapped density, compressibility index, Hausner’s ratio, weight, thickness, and hardness) were found to lie within the specifications. Dissolution study was performed in USP type II apparatus at 100 RPM in 0.1 HCL for 2 hours followed by pH 6.8 phosphate buffer. From the results of the in vitro study it appears that the release of the Zidovudine was significantly influenced by the characteristics of the polymer used.